Parkinson's Disease

all catalysts(0)

nothing on the calendar yet

News(10)

• AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
  The FDA approved AbbVie’s tavapadon, a next-generation therapy for Parkinson’s disease that's expected to provide the symptom relief of its predecessors but with fewer side effects. The dopamine ag…
  endpoints · 8d ago
• With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
  Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…
  fiercebiotech · 16d ago
• A Parkinson's biotech debut, fundraising campaign and licensing deal
  Plus news about Altis Labs, Matisse Pharmaceuticals, AstraZeneca, Novo, Longeveron, Connexus Therapeutics and Avacta. A new Parkinson’s biotech: The Michael J. Fox Foundation is supporting a non-ha…
  endpoints · 17d ago
• SK pens $315M pact with fellow South Korean company for Parkinson’s prospect
  SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer.
  fiercebiotech · 17d ago
• Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
  While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…
  biospace · 26d ago
• 10 life sciences startups selected for accelerator program
  Seven of the 10 companies participating in the fall cohorts of MassBio and SCbio’s Drive program are based in the United States, including four in Massachusetts.
  biospace · 1mo ago
• 9 midsize drugmakers climb aboard Trump’s MFN train
  Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…
  biospace · 1mo ago
• MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
  Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
  fiercebiotech · 1mo ago
• BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program
  BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather…
  fiercebiotech · 1mo ago
• Lilly drops another gene therapy trial from $1B Prevail buyout
  Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.
  fiercebiotech · 2mo ago